Research & Development
PaxVax has developed and in-licensed different technologies to help advance vaccine candidates to the clinic and eventually to market. The company has successfully brought four vaccine candidates from the bench into clinical trials in humans. PaxVax has worked successfully on both bacterial and viral vaccines as well as on different strategic approaches to vaccine development such as inactivation, live-attenuation and virosome technology. A number of PaxVax vaccine candidates utilize new technologies that the company has pioneered, such as Ad4/Ad7 vectors and the A549 cell substrate.
Today, PaxVax maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California, USA, and Thörishaus, Switzerland. These facilities include:
- Early-stage preclinical R&D
- Clinical study support
- GMP drug product manufacturing
- Drug substance sterile fill and finish
- Packaging infrastructure
PaxVax manufactures Vivotif® for all markets in its GMP-certified facility in Thörishaus, Switzerland. Vaxchora will be manufactured for the U.S. market in San Diego, California.
PaxVax has established legal entities and commercial infrastructure to market, sell and distribute vaccines in the United States, United Kingdom, Italy, Spain and Switzerland.
In countries where PaxVax does not maintain its own commercial operations, the company has signed agreements for the sale, marketing and distribution of Vivotif®. These agreements are in place with Novartis in Germany, bioCSL in Australia, New Zealand and the Pacific Isles and Valneva AB in Canada, Denmark, Finland, Norway and Sweden. In Germany, Vivotif® is sold under the brand name Typhoral®.